# US 2026/0218198 A1 · NOVEL FAS RNAi THERAPEUTICS AND USES THEREOF

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0218198 A1
- Document ID: US20260218198A1
- Status: Published application
- Kind: A1
- Application number: 19/141,294
- Filed: 2023-12-20
- Published: 2026-07-30
- Earliest claimed: 2022-12-21
- Assignees: Eli Lilly and Company
- Applicants: Eli Lilly and Company
- Inventors: Patrick Joseph ANTONELLIS; Seth Andrew BAWEL; Matthew Joseph HAMANG; Theodore Curtis JESSOP; Gregory Lawrence LACKNER; Jibo WANG; Takako WILSON
- Web page: https://patentgrep.com/patent/US20260218198A1

## CPC

- C12N 15/1138: {against receptors or cell surface proteins}
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/315: Phosphorothioates
- C12N 2310/3183: Diol linkers, e.g. glycols or propanediols
- C12N 2310/321: 2'-O-R Modification
- C12N 2310/322: 2'-R Modification
- C12N 2310/332: Abasic residue
- C12N 2310/351: Conjugate
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to novel therapeutic compounds, known as RNAi agents, that decrease expression of the FAS receptor (expressed by the FAS gene), thereby decreasing expression of FAS mRNA and protein expression. Such RNAi agents are useful in the treatment of diseases involving the regulation of FAS expression and function, such as autoimmune hepatitis.

## Claims

### Claim 1

An RNAi agent for reducing FAS gene expression, wherein the RNAi agent comprises a delivery moiety of Formula I conjugated to R, wherein R is a double stranded RNA (dsRNA) comprising an antisense strand and a sense strand:
wherein R is conjugated to connection point E of Formula I, optionally via a linker,
wherein the sense strand and the antisense strand form a duplex region, and
wherein the antisense strand comprises a region of complementarity to a FAS mRNA target sequence of SEQ ID NO: 1, and wherein the sense and antisense strand each optionally comprise one or more modified nucleotides and one or more modified internucleotide linkages.

### Claim 2 (depends on 1)

The RNAi agent of claim 1, wherein Formula I is conjugated to the sense strand, optionally via a linker.

### Claim 3 (depends on 2)

The RNAi agent of claim 2, wherein Formula I is conjugated to the 3′ terminal nucleotide of the sense strand, optionally via a linker.

### Claim 4 (depends on 1)

The RNAi agent of claim 1, wherein the antisense strand is 15 to 50 nucleotides in length.

### Claim 5 (depends on 1)

The RNAi agent of claim 1, wherein the sense strand is 15 to 50 nucleotides in length.

### Claim 6 (depends on 1)

The RNAi agent of claim 1, wherein the antisense strand is between 18 and 23 nucleotides in length.

### Claim 7 (depends on 1)

The RNAi agent of claim 1, wherein the sense strand is between 18 and 21 nucleotides in length.

### Claim 8 (depends on 1)

The RNAi agent of claim 1, wherein the antisense strand is 23 nucleotides in length and the sense strand is 21 nucleotides in length.

### Claim 9 (depends on 1)

The RNAi agent of claim 1, wherein the region of complementarity is at least 18 nucleotides in length.

### Claim 10 (depends on 1)

The RNAi agent of claim 1, wherein the antisense strand comprises a sequence selected from the group consisting of SEQ ID NO: 2 to SEQ ID NO: 112.

### Claim 11 (depends on 1)

The RNAi agent of claim 1, wherein the antisense strand comprises at least 18 contiguous nucleotides of a sequence selected from the group consisting of SEQ ID NOs: 224 to 334, 337, 338, 573, and 577.

### Claim 12 (depends on 1)

The RNAi agent of claim 1, wherein the antisense strand has a nucleotide sequence selected from the group consisting of SEQ ID NOs: 224-334, 337, 338, 573, and 577, or a sequence having at least 90% sequence identity thereto.

### Claim 13 (depends on 1)

The RNAi agent of claim 1, wherein the sense strand is selected from the group consisting of SEQ ID NOs: 113 to 223, 335, 336, 572, and 576, or a sequence having at least 90% sequence identity thereto.

### Claim 14 (depends on 1)

The RNAi agent of claim 1, wherein the duplex region between the sense strand and the antisense strand comprises 0, 1, 2, or 3 mismatches between the sense strand and the antisense strand.

### Claim 15 (depends on 1)

The RNAi agent of claim 1, wherein the sense strand comprises a first nucleic acid sequence and the antisense strand comprises a second nucleic acid sequence, wherein the first nucleic acid sequence and the second nucleic acid sequence are selected from the group consisting of:
a. the first nucleic acid sequence has at least 95% sequence identity to SEQ ID NO: 129, and the second nucleic acid sequence has at least 95% sequence identity to SEQ ID NO: 240;
b. the first nucleic acid sequence has at least 95% sequence identity to SEQ ID NO: 116, and the second nucleic acid sequence has at least 95% sequence identity to SEQ ID NO: 227;
c. the first nucleic acid sequence has at least 95% sequence identity to SEQ ID NO: 151, and the second nucleic acid sequence has at least 95% sequence identity to SEQ ID NO: 262;
d. the first nucleic acid sequence has at least 95% sequence identity to SEQ ID NO: 128, and the second nucleic acid sequence has at least 95% sequence identity to SEQ ID NO: 239; and
e. the first nucleic acid sequence has at least 95% sequence identity to SEQ ID NO: 155, and the second nucleic acid sequence has at least 95% sequence identity to SEQ ID NO: 266.

### Claim 16 (depends on 1)

The RNAi agent of claim 1, wherein the sense strand comprises a first nucleic acid sequence and the antisense strand comprises a second nucleic acid sequence, wherein the first nucleic acid sequence and the second nucleic acid sequence are selected from the group consisting of:
a. the first nucleic acid sequence comprises SEQ ID NO: 129, and the second nucleic acid sequence comprises SEQ ID NO: 240;
b. the first nucleic acid sequence comprises SEQ ID NO: 116, and the second nucleic acid sequence comprises SEQ ID NO: 227;
c. the first nucleic acid sequence comprises SEQ ID NO: 151, and the second nucleic acid sequence comprises SEQ ID NO: 262;
d. the first nucleic acid sequence comprises SEQ ID NO: 128, and the second nucleic acid sequence comprises SEQ ID NO: 239; and
e. the first nucleic acid sequence comprises SEQ ID NO: 155, and the second nucleic acid sequence comprises SEQ ID NO: 266.

### Claim 17 (depends on 16)

The RNAi agent of claim 16, wherein the sense strand or the antisense strand each independently comprise one or more modified nucleotides.

### Claim 18 (depends on 17)

The RNAi agent of claim 17, wherein the sense strand or the antisense strand each independently comprise one or more modified nucleotides, and the modified nucleotides are independently 2′ fluoro modified nucleotide residues, 2′-O-methyl modified nucleotides, or glycol nucleic acid (GNA) nucleotides.

### Claim 19 (depends on 18)

The RNAi agent of claim 18, wherein the sense strand comprises one or more modified nucleotide residues, and wherein at least one modified nucleotide residue is a GNA nucleotide that is present in an internal position of the sense strand.

### Claim 20 (depends on 19)

The RNAi agent of claim 19, wherein each nucleotide of the sense strand and each nucleotide of the antisense strand is a modified nucleotide.

### Claim 21 (depends on 20)

The RNAi agent of claim 20, wherein the antisense strand is 23 nucleotides in length and wherein each nucleotide of the antisense strand is a modified nucleotide, and 2′ fluoro modified nucleotides are present at
a. Positions 2, 3, 7, 14, and 16 from the 5′ end of the antisense strand; or
b. Positions 2, 5, 7, 14, and 16 from the 5′ end of the antisense strand; or
c. Positions 2, 3, 8, 14, and 16 from the 5′ end of the antisense strand; or
d. Positions 2, 5, 8, 14, and 16 from the 5′ end of the antisense strand; or
e. Positions 2, 6, 14, and 16 from the 5′ end of the antisense strand.

### Claim 22 (depends on 21)

The RNAi agent of claim 21, wherein the sense strand and antisense strand each independently comprise one or more modified internucleotide linkages, and wherein each modified internucleotide linkage is a phosphorothioate linkage.

### Claim 23 (depends on 22)

The RNAi agent of claim 22, wherein the sense strand and antisense strand each independently comprise four phosphorothioate linkages.

### Claim 24 (depends on 22)

The RNAi agent of claim 22, wherein the 5′ terminal nucleotide of the antisense strand comprises a phosphate group or a phosphate analog.

### Claim 25 (depends on 1)

The RNAi agent of claim 1, wherein the antisense strand comprises a sequence selected from the group consisting of SEQ ID NOs: 340, 342, 344, 346, 348, 350, 352, 354, 356, 358, 360, 362, 364, 366, 368, 370, 372, 374, 376, 378, 380, 382, 384, 386, 388, 390, 392, 394, 396, 398, 400, 402, 404, 406, 408, 410, 412, 414, 416, 418, 420, 422, 424, 426, 428, 430, 432, 434, 436, 438, 440, 442, 444, 446, 448, 450, 452, 454, 456, 458, 460, 462, 464, 466, 468, 470, 472, 474, 476, 478, 480, 482, 484, 486, 488, 490, 492, 494, 496, 498, 500, 502, 504, 506, 508, 510, 512, 514, 516, 518, 520, 522, 524, 526, 528, 530, 532, 534, 536, 538, 540, 542, 544, 546, 548, 550, 552, 554, 556, 558, 560, 562, 563, 566, 567, 569, 570, 571, 575, 579, 581, 583, 585, or a sequence having at least 90% sequence identity thereto, wherein the 5′ terminal nucleotide of the antisense strand comprises a vinyl phosphonate, a phosphate, or a hydroxyl group.

### Claim 26 (depends on 1)

The RNAi agent of claim 1, wherein the sense strand comprises a sequence selected from the group consisting of SEQ ID NOs: 339, 341, 343, 345, 347, 349, 351, 353, 355, 357, 359, 361, 363, 365, 367, 369, 371, 373, 375, 377, 379, 381, 383, 385, 387, 389, 391, 393, 395, 397, 399, 401, 403, 405, 407, 409, 411, 413, 415, 417, 419, 421, 423, 425, 427, 429, 431, 433, 435, 437, 439, 441, 443, 445, 447, 449, 451, 453, 455, 457, 459, 461, 463, 465, 467, 469, 471, 473, 475, 477, 479, 481, 483, 485, 487, 489, 491, 493, 495, 497, 499, 501, 503, 505, 507, 509, 511, 513, 515, 517, 519, 521, 523, 525, 527, 529, 531, 533, 535, 537, 539, 541, 543, 545, 547, 549, 551, 553, 555, 557, 559, 561, 564, 565, 568, 574, 578, 580, 582, 584 or a sequence having at least 90% sequence identity thereto, wherein the 5′ terminal nucleotide of the antisense strand comprises a vinyl phosphonate, a phosphate, or a hydroxyl group.

### Claim 27 (depends on 1)

The RNAi agent of claim 1, wherein the antisense strand comprises a sequence selected from the group consisting of SEQ ID NOs: 587, 589, 591, 593, 595, 597, 599, 601, 603, 605, 607, 609, 611, 613, 615, 617, 619, 621, 623, 625, 627, 629, 631, 633, 635, 637, 639, 641, 643, 645, 647, 649, 651, 653, 655, 657, 659, 661, 663, 665, 667, 669, 671, 673, 675, 677, 679, 681, 683, 685, 687, 689, 691, 693, 695, 697, 699, 701, 703, 705, 707, 709, 711, 713, 715, 717, 719, 721, 723, 725, 727, 729, 731, 733, 735, 737, 739, 741, 743, 745, 747, 749, 751, 753, 755, 757, 759, 761, 763, 765, 767, 769, 771, 773, 775, 777, 779, 781, 783, 785, 787, 789, 791, 793, 795, 797, 799, 801, 803, 805, 807, 813, 815, 817, 819, or a sequence having at least 90% sequence identity thereto.

### Claim 28 (depends on 1)

The RNAi agent of claim 1, wherein the sense strand comprises a sequence selected from the group consisting of SEQ ID NOs: 588, 590, 592, 594, 596, 598, 600, 602, 604, 606, 608, 610, 612, 614, 616, 618, 620, 622, 624, 626, 628, 630, 632, 634, 636, 638, 640, 642, 644, 646, 648, 650, 652, 654, 656, 658, 660, 662, 664, 666, 668, 670, 672, 674, 676, 678, 680, 682, 684, 686, 688, 690, 692, 694, 696, 698, 700, 702, 704, 706, 708, 710, 712, 714, 716, 718, 720, 722, 724, 726, 728, 730, 732, 734, 736, 738, 740, 742, 744, 746, 748, 750, 752, 754, 756, 758, 760, 762, 764, 766, 768, 770, 772, 774, 776, 778, 780, 782, 784, 786, 788, 790, 792, 794, 796, 798, 800, 802, 804, 806, 808, 809, 810, 811, 812, 814, 816, 818, or a sequence having at least 90% sequence identity thereto.

### Claim 29 (depends on 1)

The RNAi agent of claim 1, wherein the sense strand comprises a first nucleic acid sequence and the antisense strand comprises a second nucleic acid sequence, wherein the first nucleic acid sequence and the second nucleic acid sequence are selected from the group consisting of:
a. the first nucleic acid sequence has at least 95% sequence identity to SEQ ID NO: 339, and the second nucleic acid sequence has at least 95% sequence identity to SEQ ID NO: 340;
b. the first nucleic acid sequence has at least 95% sequence identity to SEQ ID NO: 341, and the second nucleic acid sequence has at least 95% sequence identity to SEQ ID NO: 342;
c. the first nucleic acid sequence has at least 95% sequence identity to SEQ ID NO: 343, and the second nucleic acid sequence has at least 95% sequence identity to SEQ ID NO: 344;
d. the first nucleic acid sequence has at least 95% sequence identity to SEQ ID NO:345, and the second nucleic acid sequence has at least 95% sequence identity to SEQ ID NO: 346;
e. the first nucleic acid sequence has at least 95% sequence identity to SEQ ID NO: 347, and the second nucleic acid sequence has at least 95% sequence identity to SEQ ID NO: 348;
f. the first nucleic acid sequence has at least 95% sequence identity to SEQ ID NO: 349, and the second nucleic acid sequence has at least 95% sequence identity to SEQ ID NO: 350;
g. the first nucleic acid sequence has at least 95% sequence identity to SEQ ID NO: 353, and the second nucleic acid sequence has at least 95% sequence identity to SEQ ID NO: 354;
h. the first nucleic acid sequence has at least 95% sequence identity to SEQ ID NO: 363 and the second nucleic acid sequence has at least 95% sequence identity to SEQ ID NO: 364; and
i. the first nucleic acid sequence has at least 95% sequence identity to SEQ ID NO: 381, and the second nucleic acid sequence has at least 95% sequence identity to SEQ ID NO: 382.

### Claim 30 (depends on 1)

The RNAi agent of claim 1, wherein the sense strand comprises a first nucleic acid sequence and the antisense strand comprises a second nucleic acid sequence, wherein the first nucleic acid sequence and the second nucleic acid sequence are selected from the group consisting of:
a. the first nucleic acid sequence has at least 95% sequence identity to SEQ ID NO: 564 or 809, and the second nucleic acid sequence has at least 95% sequence identity to SEQ ID NO: 571;
b. the first nucleic acid sequence has at least 95% sequence identity to SEQ ID NO: 568 or 811, and the second nucleic acid sequence has at least 95% sequence identity to SEQ ID NO: 567;
c. the first nucleic acid sequence has at least 95% sequence identity to SEQ ID NO: 580 or 814, and the second nucleic acid sequence has at least 95% sequence identity to SEQ ID NO: 581 or 815;
d. the first nucleic acid sequence has at least 95% sequence identity to SEQ ID NO: 582 or 816, and the second nucleic acid sequence has at least 95% sequence identity to SEQ ID NO: 583 or 817; and
e. the first nucleic acid sequence has at least 95% sequence identity to SEQ ID NO: 584 or 818, and the second nucleic acid sequence has at least 95% sequence identity to SEQ ID NO: 585 or 819.

### Claim 31 (depends on 1)

The RNAi agent of claim 1, wherein the sense strand comprises a first nucleic acid sequence and the antisense strand comprises a second nucleic acid sequence, wherein the first nucleic acid sequence and the second nucleic acid sequence are selected from the group consisting of:
a. the first nucleic acid sequence comprises SEQ ID NO: 564 or 809, and the second nucleic acid sequence comprises SEQ ID NO: 571;
b. the first nucleic acid sequence comprises SEQ ID NO: 568 or 811, and the second nucleic acid sequence comprises SEQ ID NO: 567;
c. the first nucleic acid sequence comprises SEQ ID NO: 580 or 814, and the second nucleic acid sequence comprises SEQ ID NO: 581 or 815;
d. the first nucleic acid sequence comprises SEQ ID NO: 582 or 816, and the second nucleic acid sequence comprises SEQ ID NO: 583 or 817; and
e. the first nucleic acid sequence comprises SEQ ID NO: 584 or 818, and the second nucleic acid sequence comprises SEQ ID NO: 585 or 819.

### Claim 32 (depends on 29)

The RNAi agent of claim 29, wherein the 5′ terminal nucleotide of the antisense strand contains a vinyl phosphonate, a phosphate group, or an OH group.

### Claim 33 (depends on 1)

The RNAi agent of claim 1, wherein R is conjugated to Formula I via a linker.

### Claim 34 (depends on 1)

The RNAi agent of claim 1, wherein R is conjugated to Formula I via a linker, and wherein linker comprises a linker of Formula II having connection points A and B or the linker comprises Formula III having connection points C and D, and wherein:
a. Formula I is conjugated to Formula II at connection point A and Formula II is conjugated to a phosphate group or a phosphorothioate group at connection point B, and the phosphate group or phosphorothioate group is further conjugated to R; or
b. Formula I is conjugated to Formula III at connection point C and Formula III is conjugated to a phosphate group or phosphorothioate group at connection point D, and the phosphate group or phosphorothioate group is further conjugated to R.

### Claim 35 (depends on 1)

The RNAi agent of claim 1, wherein R is conjugated to Formula I via a linker, and wherein the linker is a linker comprising Formula III having connection points C and D:
and wherein Formula I is conjugated to Formula III at connection point C and Formula III is conjugated to a phosphate group or a phosphorothioate group at connection point D, and the phosphate group or the phosphorothioate group is further conjugated to R.

### Claim 36 (depends on 1)

The RNAi agent of claim 1, wherein the RNAi agent decreases expression of the FAS gene in a liver cell, as compared to a control.

### Claim 37 (depends on 1)

The RNAi agent of claim 1, wherein the linker is of Formula III and Formula III is conjugated to a phosphate group at connection point D, and wherein the sense strand comprises a first nucleic acid sequence and the antisense strand comprises a second nucleic acid sequence, wherein the first nucleic acid sequence comprises SEQ ID NO: 564, and the second nucleic acid sequence comprises SEQ ID NO: 571.

### Claim 38

(canceled)

### Claim 39 (depends on 1)

A pharmaceutical composition comprising the RNAi agent of claim 1, and one or more pharmaceutically acceptable excipients.

### Claim 40

(canceled)

### Claim 41 (depends on 1)

A method of treating autoimmune hepatitis (AIH) in a patient in need thereof, comprising administering to the patient the RNAi agent of claim 1, or a pharmaceutical composition thereof.

### Claim 42 (depends on 1)

A method of decreasing FAS expression in a cell, comprising contacting the cell with the RNAi agent of claim 1.

### Claim 43 (depends on 42)

The method of claim 42, wherein the method further comprises incubating the cell for a time sufficient for decreasing the level of FAS mRNA by at least 50% as compared to an untreated or control treated cell.

### Claim 44 (depends on 37)

A method of treating autoimmune hepatitis (AIH) in a patient in need thereof, comprising administering to the patient the RNAi agent of claim 37, or a pharmaceutical composition thereof.
